Inimmune raises $22 Million in Series A Funding Led by Two Bear Capital – Investment believed to be largest Series A funding in state history – Montana Career Opportunity
Inimmune, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. It was the Missoula-based company’s first outside investment. The round was led by Two Bear Capital, a new firm based in Whitefish, Montana. Two Bear Capital Founder and Managing Partner Michael Goguen will join Inimmune’s board of directors.
“We are excited to partner with Two Bear Capital for this Series A investment. We could have looked outside of Montana for investors but were happy to find a local VC firm that connected with our vision to grow a world-class biotech company right here in Montana,” said Dr. Jay Evans, President and CEO at Inimmune. The company plans to use the Series A investment to advance at least two late-stage pre-clinical drug candidates in oncology and allergy through Phase I human clinical trials.
Investment believed to be largest Series A funding in state history; Inimmune specializes in adjuvants for vaccines and has been developing COVID-19 vaccine
Postdoctoral Research Associate Position Inimmune Corporation has an exciting opportunity available immediately in our R&D Center for a postdoctoral research associate position in synthetic chemistry.
Montana biotech company Inimmune receives Small Business Innovation Research Contract to discover novel treatments for seasonal allergies
“The new immunotherapy approach developed at Inimmune for the treatment of seasonal allergies has the potential to offer rapid desensitization, better efficacy, lower side-effects and lower cost compared to currently available antigen-specific immunotherapies.”
Scott Whittenburg, vice president of research and creative scholarship at UM, called the grant a big step forward in the university’s push to develop translational medicine.